Bristol And AstraZeneca Make A Splash In Diabetes With Joint Purchase Of Amylin
Executive Summary
Bristol-Myers’ and AstraZeneca’s deal to acquire Amylin Pharmaceuticals for $7 billion, announced June 29, reaffirms the partners’ commitment to the vast and growing type 2 diabetes market, even if the competition is intense and the companies’ five-year-old alliance got off to a rocky start.
You may also be interested in...
AstraZeneca’s Seasoned Dealmaker Grady On Strategy To Grow Pipeline
AstraZeneca’s Shaun Grady is an affable dealmaker whose talents – honed over three decades inside the group – are being put to the test as global business development head to help ensure Britain’s second-biggest drugmaker can successfully transform itself, its therapy focus and pipeline. He tells In Vivo about his role leading AZ’s transaction execution, due diligence and alliance and integration management, while overseeing its collaborative “externalization” program, licensing and partnering, M&A and divestments.
AstraZeneca, Flying Solo, Sees Momentum Take Off In Diabetes
The company launched three diabetes drugs in 2014, just after breaking off a joint venture with Bristol-Myers and taking over full control of the business. U.S. President Paul Hudson talked about the evolution of AstraZeneca’s diabetes business – and where it stands today – in a recent interview.
AstraZeneca’s Diabetes Combo Could Help Stake Its Independence From Pfizer
Positive trial results buoy the British pharma’s late-stage pipeline as it battles to keep its independence from Pfizer. The saxagliptin/dapagliflozin combo is a cornerstone of the diabetes franchise.